Laura Calabrese
Siena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Nasal biopsy in ANCA-associated vasculitis: a game changer or a false friend?
Journal: Rhinology
Published: July 14, 2026
Screening for Eating Disorders in Psoriasis Patients: A Multicenter Cross-Sectional Study.
Journal: Psoriasis (Auckland, N.Z.)
Published: July 08, 2026
Correction to: IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry.
Journal: Clinical and experimental rheumatology
Published: May 07, 2026
Type I and II Interferon Signalling Characterizes the Transcriptional Landscape of Sweet Syndrome.
Journal: Experimental dermatology
Published: March 02, 2026
T2-Reg: a regional web registry on Th2-mediated diseases.
Journal: Italian journal of dermatology and venereology
Published: January 12, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.
Journal: Acta dermato-venereologica
Published: January 09, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.
Journal: Acta dermato-venereologica
Published: January 09, 2026
Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study.
Journal: Frontiers in immunology
Published: December 18, 2025
Cutting-edge multiomic approaches shed light on the interleukin-36 axis in Sweet syndrome.
Journal: The British journal of dermatology
Published: November 10, 2025
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: November 07, 2025
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.
Journal: Clinical and experimental dermatology
Published: October 21, 2025
Dermatological adverse events during hematological and oncological therapies (Bruton's tyrosine kinase inhibitors and mogamulizumab): an Italian retrospective multicenter study.
Journal: Italian journal of dermatology and venereology
Published: October 03, 2025
Last Updated: 09/26/2026